Jun 04, 2019
Proteostasis Therapeutics Receives Orphan Drug Designation in the EU for PTI-428 for the Treatment of Cystic Fibrosis
Jun 03, 2019
Proteostasis Therapeutics Announces Presentations and Hosts Educational Symposium at the 42nd European Cystic Fibrosis Conference
May 15, 2019
Proteostasis Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference
Mar 07, 2019
Proteostasis Therapeutics Appoints David Arkowitz to Board of Directors
Feb 27, 2019
Proteostasis Selected to Join European Consortium to Pioneer Personalized Medicine in Cystic Fibrosis
Feb 20, 2019
Proteostasis Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Dec 20, 2018
Proteostasis Therapeutics Provides Clinical Enrollment Update
Dec 17, 2018
Proteostasis Therapeutics Announces Global License Agreement with Genentech
Oct 23, 2018
Proteostasis Therapeutics Prices Public Offering of Common Stock
Oct 22, 2018
Proteostasis Therapeutics Announces Proposed Public Offering of Common Stock
Oct 17, 2018
Proteostasis Therapeutics Announces Positive Preliminary Results from Proprietary Doublet in Cystic Fibrosis Patients
Sep 27, 2018
Proteostasis Therapeutics to Present at the Cantor Global Healthcare Conference
Jun 25, 2018
Proteostasis Added to the Russell 3000® Index
Jun 06, 2018
Proteostasis Announces Positive Data from Ongoing Phase 1 Study of PTI-801 in Cystic Fibrosis Patients on Background Orkambi® Therapy
Jun 01, 2018
Proteostasis Announces Presentations at the 41st European Cystic Fibrosis Society Conference
May 31, 2018
Proteostasis Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
May 08, 2018
Proteostasis Announces Formation of Independent Steering Committee of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for PTI-428 in Cystic Fibrosis
Apr 17, 2018
Proteostasis Receives Endorsement from the Cystic Fibrosis Foundation's Therapeutic Development Network for the Study of the Company's Amplifier, PTI-428, in CF Subjects on Background Symdeko(TM) Therapy
Apr 04, 2018
Proteostasis Therapeutics Receives FDA Fast Track Designation for Triple Combination Program in Patients with Cystic Fibrosis
Mar 19, 2018
Proteostasis Therapeutics Announces Proposed Public Offering of Common Stock